Overcoming adaptive therapy resistance in AML by targeting immune response pathways

Targeted inhibitors to oncogenic kinases demonstrate encouraging clinical responses early in the treatment course; however, most patients will relapse because of target-dependent mechanisms that mitigate enzyme-inhibitor binding or through target-independent mechanisms, such as alternate activation...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Transl Med
Main Authors: Melgar, Katelyn, Walker, Morgan M., Jones, LaQuita M., Bolanos, Lyndsey C., Hueneman, Kathleen, Wunderlich, Mark, Jiang, Jiang-Kang, Wilson, Kelli M., Zhang, Xiaohu, Sutter, Patrick, Wang, Amy, Xu, Xin, Choi, Kwangmin, Tawa, Gregory, Lorimer, Donald, Abendroth, Jan, O’Brien, Eric, Hoyt, Scott B., Berman, Ellin, Famulare, Christopher A., Mulloy, James C., Levine, Ross L., Perentesis, John P., Thomas, Craig J., Starczynowski, Daniel T.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6985905/
https://ncbi.nlm.nih.gov/pubmed/31484791
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aaw8828
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados